Background: It is unclear whether the risk of bleeding from brain arteriovenous malformations is higher during pregnancy, delivery, or puerperium. We compared occurrence of brain arteriovenous malformation hemorrhage in women during this period with occurrence of hemorrhage outside this period during their fertile years.
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Arteriovenous malformation, intracranial hemorrhage, pregnancy, self-controlled case-series Received: 10 June 2016; accepted: 13 November 2016 Brain arteriovenous malformations (BAVMs) are abnormal connections between arteries and veins leading to arteriovenous shunting with an intervening network of vessels-the so-called nidus-and without a true capillary bed. 1, 2 The most frequent presentation of BAVMs is intracranial hemorrhage, which has a peak incidence in the third and fourth decade. 3 Various case-reports and case-series of patients with BAVMs have reported the occurrence of hemorrhage during pregnancy. [4] [5] [6] [7] One study on natural history reported that one in four women aged between 20 and 29 years, presenting with hemorrhage, were pregnant. 7 Some studies have suggested that women have an increased risk of hemorrhage during pregnancy, [8] [9] [10] whereas another study did not. 11 Investigating the effect of transient exposures such as pregnancy is methodologically challenging. Most previous studies compared hemorrhage rates during pregnant and non-pregnant follow-up, [9] [10] [11] often in selected patient groups such as women referred for radiosurgery. 10, 11 In the past, incorrect interpretation of retrospective data in one study has led to recommendations to sterilize women with BAVMs. 8, 11 The effect of transient exposures on acute events can be studied with self-controlled methods, which use patients as their own controls in order to ascertain whether there is an association between a transient exposure and the acute event. Thus, confounding by variation in patients' characteristics can be avoided. [12] [13] [14] Using two different self-controlled methods, we investigated in women with a ruptured BAVM whether the relative chance of rupture is higher during pregnancy, delivery, and puerperium than outside this period.
Methods
We estimated the relative rate of BAVM hemorrhage during pregnancy, delivery, and puerperium using a case-crossover design (supplementary Figure 1 ) as primary analysis, and according to the self-controlled case-series method (supplementary Figure 2 ) as secondary analysis. [12] [13] [14] Only the first BAVM hemorrhage during untreated follow-up was used (supplementary Figures 1 and 2) . In both analyses, we assumed a nine-month period (from the 7th week after conception through the 6th week after delivery) for the time at risk during pregnancy, delivery, and puerperium. The first six weeks of pregnancy were excluded because the hemodynamic changes in relation to pregnancy are less prominent during this time. Only the first BAVM hemorrhage during untreated follow-up was used in both analyses (supplementary Figures 1 and 2 ).
Patients
We included all women with BAVM hemorrhage at fertile age (i.e., from 16 years up to and including 41 years), who were seen in one of four Dutch university hospitals (VUMC Amsterdam, AMC Amsterdam, Leiden UMC, and UMC Utrecht; inclusion period 1990-2006) or who were included in the populationbased Scottish Audit of Intracranial Vascular Malformations study (SAIVMs; inclusion periods 1999-2003 and 2006-2010) . The women in the Dutch hospitals were retrospectively identified through multiple, overlapping registries in each hospital to ensure that no patients were missed: stroke registries, diagnosis registration systems, pathology registries, operation registries, registries of embolized and radiosurgically treated patients, and neurovascular meetings. The SAIVMs is an on-going National Health Service clinical audit of adults who were aged 16 years or older and were resident in Scotland when first diagnosed with any type of intracranial vascular malformation. The Scottish Intracranial Vascular Malformations Study is a prospective, population-based cohort study in which anonymous data extracts from SAIVMs are used. Patients were identified through multiple overlapping sources of case ascertainment, which included a Scotland-wide collaborative network of neurologists, neurosurgeons, stroke physicians, radiologists, and pathologists, and central registers of hospital discharge records and death certificates. 15 The fertile period was defined from 16 years up to and including 41 years because in the general population 99% of pregnancies occur in women in this age range (Statistics Netherlands, www.statline.cbs.nl). The diagnosis of BAVM was confirmed with radiological or pathological examination. Patients who were diagnosed with hereditary hemorrhagic telangiectasias were excluded. BAVM hemorrhage was defined as a symptomatic clinical event, with signs of intracranial blood on brain imaging performed at the time of symptoms, lumbar puncture, or on post-mortem examination referable to the BAVM or an associated, flow-related aneurysm. All hemorrhages were classified as having occurred either during pregnancy, delivery, or puerperium, or outside this period.
In patients with a hemorrhage during pregnancy, delivery, or puerperium, we retrieved information on maternal age, gestational age at the time of hemorrhage, mode of delivery, location and treatment of the BAVM, and maternal (according to the Glasgow Outcome Scale 16 ) and fetal outcome.
Maternity data
For women in the Dutch cohort, we used information regarding live-born children that was given by patients who participated in a survey to investigate familial occurrence of BAVMs, 17 and information retrieved from the medical files.
For women in the Scottish cohort, obstetric episodes were obtained from the maternity inpatient and daycase discharges dataset by the Information Services Division (ISD) in the Scottish Morbidity Records (SMR02). The ISD has consistently achieved a national coverage of 98% of all births (www.isdscotland. org/Health-Topics/Maternity-and-Births/Births/). The SMR02 maternity data were cross-checked with any information about previous pregnancies in the case records of the women. If a patient, who met the inclusion criteria, did not link with the SMR02 dataset, her case records were searched for references to any children or previous pregnancies. In most cases, these women had never been pregnant. For the women who did not link with the SMR02 dataset, and whose case records suggested existing children, the patient or her GP was contacted and asked to provide the delivery dates and gestations of her children.
In both Dutch and Scottish women, abortions and miscarriages were not taken into account.
Statistical analysis
First, we estimated the relative hemorrhage rates during pregnancy, delivery, or puerperium, and during nonexposed time, restricting the duration of follow-up to the time until the first hemorrhage, for the total cohort and the Dutch and Scottish cohorts separately. Subsequently, the relative rate of BAVM hemorrhage during pregnancy, delivery, and puerperium was estimated using the case-crossover design as primary analysis and the self-controlled case-series method as secondary analysis. [12] [13] [14] We planned to analyze the Dutch and Scottish cohorts separately, and subsequently combined.
In the case-crossover analysis (supplementary Figure  1) , we expressed the time at risk of a woman until occurrence of her first hemorrhage during her fertile years in ''9-months' periods'' by multiplying the number of years by 12/9 yielding relative rates with 95% confidence intervals (CIs). Analyses were performed with SPSS (version 20).
In the self-controlled case-series analysis (supplementary Figure 2 ), we studied the first hemorrhage because hemorrhage may affect subsequent exposure (e.g., a woman may die after hemorrhage or may be advised against pregnancy). We used the extension to the self-controlled case-series method for censored, perturbed, or curtailed post-event exposures to obtain unbiased relative rate estimates. 14 Analyses were performed using STATA (Version 8.1). CIs were estimated using bootstrapping.
Review of the literature
We searched PubMed for case-series and systematic reviews reporting on women with BAVMs and their hemorrhage risk during pregnancy, delivery, and puerperium published in English on September 1, 2016, with the search terms (intracranial arteriovenous malformations OR brain arteriovenous malformations) AND intracranial hemorrhage AND pregnancy.
Ethical approval
The Dutch study was approved by the institutional ethical committee of the University Medical Center Utrecht. 17 The Multicenter Research Ethics Committee for Scotland (MREC/98/0/48) and the Fife and Forth Valley Research Ethics Committee (08/S0501/76) approved the under taking of observational studies (to which an opt-out consent policy applied) and postal questionnaire studies (which required opt-in consent).
Results
In 95 (28%) of 340 women in the Dutch and in 44 (22%) of 202 women in the Scottish cohort, hemorrhage occurred during their fertile lives (Table 1) .
With respect to case-ascertainment in the Scottish cohort, three patients were reported by ISD only and not by one of the Scottish neuroscience centers. One of these three women experienced BAVM hemorrhage during her pregnancy (supplementary Table 2 ).
On average, women in the Dutch cohort were slightly older than women in the Scottish cohort (observed difference 3.0 years, 95% CI 0.62-5.4) at the time they gave birth to their first child. The proportion of lobar BAVMs was higher in the Scottish cohort (observed difference 21%, 95% CI 4.6-38).
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Dutch cohort
A total of 17 women experienced BAVM hemorrhage during 56 years at risk (relative hemorrhage rate 30%/ year, 95% CI 18-49%), and in 78 women, BAVM rupture occurred during 1231 non-pregnant person years (relative hemorrhage rate 6.3%/year, 95% CI 5.0-7.9%). The case-crossover method yielded a relative rate during pregnancy, delivery, or puerperium of 6.8 (95% CI, 3.6-13), and the self-controlled case-series of 7.1 (95% CI, 3.4-13).
Scottish cohort
Three women experienced a hemorrhage during a total of 35 years at risk (relative hemorrhage rate 8.6%/year, 95% CI 1.8-25%), and 41 hemorrhages occurred during 597 non-pregnant person years (relative hemorrhage rate 6.9%/year, 95% CI 4.9-9.3%). The casecrossover method yielded a relative rate during pregnancy, delivery, or puerperium of 1.3 (95% CI, 0.39-4.1), and the self-controlled case-series a relative rate of 1.7 (95% CI, 0.0-4.4).
Combined cohort
Given the limited overlap of the CIs of the point estimates, we refrained from pooling both cohorts.
Review of the literature
We identified five case-series [8] [9] [10] [11] 18 and two systematic reviews (supplementary Table 3 ). 4, 19 Two narrative reviews were excluded. 20, 21 The most recent case-series-using a self-controlled method in large hospital-based, retrospective Chinese cohort-showed a decreased hemorrhage risk associated with pregnancy, delivery, and puerperium. 19 Another retrospective study concluded that the hemorrhage risk during pregnancy was not increased, 11 whereas two studies showed an increased risk of BAVM hemorrhage during pregnancy 9 or during the second trimester only. 10 
Discussion
In the Dutch hospital cohort of women with a ruptured BAVM, the relative rupture rate was approximately seven times higher during pregnancy, delivery, and puerperium than outside this period. The analyses in the smaller population-based Scottish cohort did not confirm this increased risk. Limited overlap of the CIs of the point estimates hampered the pooled analysis. The observed difference in hemorrhage risk during pregnancy, delivery, and puerperium between the Dutch and Scottish cohorts may have been due to chance, especially given the sample sizes. Still, referral bias may have played a role. One would think that a woman with BAVM hemorrhage is more likely to get referred to a neuroscience center if she is pregnant. Yet, one Scottish woman who experienced a BAVM hemorrhage during pregnancy was only reported to the researchers by the ISD but not by one of the collaborating neuroscience centers. In the Netherlands, we would expect that all young women with BAVM hemorrhage are referred to a neurosurgical center unless they have died in a local hospital. Geographic or ethnic differences are unlikely to explain the disparate risk during pregnancy, delivery, and puerperium, as both in The Netherlands and Scotland, the large majority of the women were Caucasian. Moreover, hemorrhage rates outside pregnancy were similar in both cohorts (6.3%/year vs. 6.9%/year), which makes it also unlikely that the higher proportion of women with lobar BAVMs included in the Scottish cohort explains the observed difference in hemorrhage risk during pregnancy.
A recent Chinese hospital-based study showed a decreased hemorrhage risk during pregnancy using the case-crossover method. 18 In this study, the relative hemorrhage rate during pregnancy, delivery, and puerperium (2.7, 12 hemorrhages/452 pregnancies; supplementary Figure 3 ) was remarkably low in comparison to the Dutch (18, 17 hemorrhages/95 pregnancies) and to the Scottish (6.8, 3 hemorrhages/44 pregnancies) cohort. The relative hemorrhage rate outside pregnancy was also lower (4.1%/year) in the Chinese study than in the Dutch (6.3%/year) and Scottish (6.9%/year) cohorts. The Chinese women were enrolled over a large time frame between 1960 and 2010, and diagnosis of both hemorrhage and BAVM is likely to have been less accurate in the earlier decades. Also, the fact that the authors included 54 patients with previous hemorrhage or BAVM treatment may have influenced their hemorrhage risk as well as the decision to become pregnant in some women, and therefore biased their results. 18 Another study, which analyzed the effect of pregnancy using Cox proportional hazards regression modeling with pregnancy as time-dependent co-variable, yielded an almost eight times increased risk of BAVM hemorrhage during pregnancy. 9 This is comparable to the results found in the Dutch cohort.
An important strength of our study is that we used two self-controlled methods [12] [13] [14] which yielded similar results. We added the self-controlled case-series as a secondary analysis because of increased power in comparison to the case-crossover design, and the possibility to explicitly control for age-and time-related effects. 14 Additionally, we censored women at the time of first hemorrhage because the rupture rate increases after a first hemorrhage, and the occurrence of BAVM hemorrhage may influence the decision to become pregnant. Moreover, our cohorts were not limited to patients who were referred for a certain treatment as in some previous studies, 10, 11 and we calculated the risk-time from the age of 16 years and not from birth. 11 Our study is limited by the small number of included women despite our efforts to improve power by combing cohorts. Secondly, case-ascertainment differed between the Dutch and Scottish cohorts, which could have contributed to the different results during pregnancy. Thirdly, in both cohorts, pregnant follow-up may have been underestimated by not including abortions and miscarriages. Additionally, pregnancies may have been missed by the ISD in Scotland, and the Dutch women might not have declared all of their pregnancies when asked. Finally, an important limitation of our study with respect to clinical applicability is that with the data we had, we could calculate relative but no absolute risks of rupture during pregnancy, delivery, and puerperium. Moreover, risks for women with unruptured BAVMs cannot be deducted from our results. It is important to realize that all women included in our study bled, and that in the majority of women, hemorrhage was the first presentation of their BAVMs (95% Dutch cohort, 98% Scottish cohort; Table 1 ).
Although our study cannot provide the final answers, which are needed for clinical practice, the results from the Dutch cohort support previous observations that the period of pregnancy, delivery, and puerperium could increase the risk of BAVM rupture in particular with increasing gestational age. Women with a BAVM should be informed of the possibility that pregnancy probably increases the risk of BAVM hemorrhage, but that the extent to which this occurs is uncertain. Given the annual hemorrhage risk of 2.3-3.0% per year, 22,23 a temporary increase during pregnancy by 1.5 as found in the Scottish cohort would not infer a considerably larger risk whereas an increase by 7 would denote a clinically significant increased hemorrhage risk. Whether or not an unruptured BAVM should be treated before conception will depend on the characteristics of the BAVM, the individualized estimated risk of hemorrhage and treatment, and the informed opinion of the patient. The shortterm results of the ARUBA trial-showing a more than three-fold increased risk of stroke and death after intervention compared with conservative management in patients with unruptured BAVMs-have to be taken into account as well as the criticisms with respect to the conduct and outcome of this trial. 24, 25 In our view, there is no reason to advise discontinuation of pregnancy or sterilization as has been done in the past.
Ideally, the effect of pregnancy on the hemorrhage risk of BAVMs should be investigated by the conduct of large multi-center prospective population-based studies because these will provide absolute risks during pregnancy for all women with BAVMs. Meanwhile, replication of this study design in larger prospectively population cohorts or individual patient data metaanalysis studies can add to the current findings.
